UNSPSC 51452003: Bunamidine

This classification denotes an antihelminthic agent with the molecular formula C25H38N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A9IW1G3P6C, chemically known as 1-naphthamidine, n,n-dibutyl-4-hexyloxy-, monohydrochloride but generally known as bunamidine, which bears US NIH Compound Identifier 13986. Bunamidine base, hydroxynaphthoate, and oxynaphthoate forms. European Medicines Agency schedules Bunamidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05974MIG.

UNSPSC 51452003 Bunamidine is a Commodity code that nominally designates a specific pharmaceutical compound, but recent state and local solicitations tagged with this code do not focus on bunamidine itself. Instead, they reflect procurement of broader pharmaceutical and medical supply categories — naloxone, generic multi-source medications, over-the-counter products, and emergency medical consumables. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), municipal fire departments (City of Tampa), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The scope of work spans annual supply contracts for emergency medications and first aid kits, direct-to-manufacturer prescription programs, and generic pharmaceutical distribution agreements serving multiple government jurisdictions and facilities.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County issued IFB 60459723LAS on June 30, 2026 (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building and a fixed-fee award based on competitive bidding. The City of Tampa issued IFB 26-P-00145 on March 25, 2026 (due March 13, 2026) for 169 line items of medical and first aid supplies totaling approximately $700,000 for the Tampa Fire Department Rescue Division, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount. Texas HHS issued RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. MMCAP issued RFP S1070000015802 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities, with awards effective July 1, 2026. The code shows limited direct activity in bunamidine procurement; opportunities are broadly pharmaceutical and medical-supply oriented rather than compound-specific.